Finance

Beta
Lists
1AEA:FRA
argenx SE - ADR
€680.00
-3.55%
(-25.00) 1D
Jun 3, 8:10:42 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 1AEA...
Open
€680.00
High
€680.00
Low
€680.00
Mkt. cap
43.24B
Avg. vol.
1.00
Volume
0.00
52-wk high
€810.00
52-wk low
€454.00
No. of employees
2K
Open
€680.00
High
€680.00
Low
€680.00
Mkt. cap
43.24B
Avg. vol.
1.00
Volume
0.00
52-wk high
€810.00
52-wk low
€454.00
No. of employees
2K
News stories
From sources across the web
Profile
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs. Wikipedia
About argenx SE - ADR
CEO-
Employees1.86K
Founded2008
Headquarters-
SectorBiotechnology
Websiteargenx.com
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
967.19M
1.15B
1.31B
1.31B
Cost of goods sold
438.44M
465.08M
521.40M
564.00M
Cost of revenue
438.44M
465.08M
521.40M
564.00M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
324.90M
336.29M
429.62M
355.00M
Operating expense
324.90M
336.29M
429.62M
355.00M
Total operating expenses
763.35M
801.37M
951.02M
919.00M
Operating income
203.84M
349.97M
359.56M
394.00M
Other non operating income
-
-
-907.00K
-
EBT including unusual items
286.90M
386.05M
403.29M
426.00M
EBT excluding unusual items
286.90M
386.05M
391.71M
426.00M
Income tax expense
41.54M
41.80M
-129.66M
60.00M
Effective tax rate
14.48%
10.83%
-32.15%
14.08%
Other operating expenses
-
-
-
-
Net income
245.36M
344.26M
532.95M
366.00M
Net profit margin
25.37%
29.90%
40.67%
27.88%
Earnings per share
-
-
-
-
Interest and investment income
38.40M
42.70M
44.95M
44.00M
Interest expense
-1.13M
-993.00K
-
-1.00M
Net interest expenses
37.27M
41.71M
44.95M
43.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
210.47M
350.35M
361.38M
395.82M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer